Alesi Surgical raises $6m to support commercial efforts

Alesi Surgical said this week that it raised $5.8 million to support commercialization of its Ultravision surgical device. Venture capital firms Panakes and Earlybird contributed to the new investment, joined by existing shareholders IP Group and Finance Wales. The company is slated to use the newly-acquired funds to drive commercial expansion of Ultravision into the U.S. In conjunction with the financing, Thom Rasche of Earlybird and Alessio Beverina of Panakes Partners will join Alesi’s board as investor directors, according to the company. “Earlybird and Panakes are 2 highly respected European venture capital companies and in such a competitive funding environment their interest in Alesi and Ultravision speaks volumes for our potential,” Alesi Surgical managing director Dominic Griffiths said in prepared remarks. “With the 2 new additions to the board we have expanded our expertise in this market and having four corporate investors places us in a strong position for future growth.” The company’s Ultravision platform recently won FDA approval and clearance by the Japanese Ministry of Health. The system uses electrostatic technology to clear the “surgical smoke”, vapor and particulate matter, that is produced by machinery used during abdominal laparoscopic surgery. The device improves visibility for surgeons and also reduces the amount of cold, dry carbon dioxide gas that a patient is exposed to during the procedure. Traditio...
Source: Mass Device - Category: Medical Devices Authors: Tags: Funding Roundup Surgical alesisurgical Source Type: news